Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Mirdametinib Provides Long-Awaited Treatment Option in NF1-Associated PN
Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma
Neoadjuvant Chemo and Concurrent Chemoradiation Is a Safe, Effective Bladder-Sparing Approach in Nonmetastatic MIBC
Some Patients With Kidney Cancer Can Stop Combination Treatment After Two Years, Fox Chase Cancer Center Study Finds
2 Commerce Drive
Cranbury, NJ 08512